Clinical Consensus Statement — Integrated Mental Health Assessment and Management
Mental health and cardiovascular disease are intrinsically linked through bidirectional pathways. Positive mental health is protective against CVD; conversely, mental health disorders (depression, anxiety, PTSD) are associated with increased CVD risk, worse prognosis, and poor medication adherence. This consensus statement provides practical guidance on screening, assessment, and integrated management of mental health in people with CVD.
Psychosocial stressors drive CVD risk through physiological and behavioral pathways. Key stressors include work stress, loneliness, socioeconomic hardship, adverse childhood experiences, and perceived discrimination.
| Consequence | Mechanism |
|---|---|
| Hypertension | Sympathetic overdrive, cortisol elevation |
| CAD | Endothelial dysfunction, plaque rupture |
| Stroke | Increased risk, especially post-acute stress |
| AF | Acute stress triggers AF; chronic increases burden |
| MI & SCD | Stress-induced cardiomyopathy; acute MI risk |
| HF | Chronic stress accelerates progression |
Depression is common in CVD. Prevalence ranges from 4–48% depending on CVD type and diagnostic method. Key populations:
| CVD Type | Prevalence |
|---|---|
| ACS/Post-MI | 31% at hospitalization; 22–40% in women <60 yrs |
| Chronic HF | 21–33% (ranges 11–67%) |
| AF | 38% (Beck Depression Inventory) |
| ICD | 11–42% (post-ICD incidence 11.3%) |
| PAH | 28% pooled (range 9–70%) |
Anxiety affects 12–37% of CVD patients, often co-occurring with depression. Prevalence is higher in women and younger patients. Untreated anxiety worsens QoL and CV prognosis.
Cardiac events can trigger PTSD (prevalence 7–35% depending on event type). PTSD is associated with increased CVD readmissions and recurrent events. Early screening and trauma-focused therapy are essential.
| Tool | Items | Sensitivity | Specificity |
|---|---|---|---|
| Whooley Questions | 2 items (mood + interest) | 95% | 65% |
| PHQ-2 | Score 0–6; ≥3 = depression | 97% | 48% |
| GAD-2 | Score 0–6; ≥3 = anxiety | 91% | 37% |
| HADS | 14 items (7 anxiety, 7 depression) | High sensitivity/specificity | Validated in CV; requires license |
| Timing | For Anxiety | For Depression |
|---|---|---|
| New diagnosis / acute event | GAD-2 then GAD-7 if positive | PHQ-2 then PHQ-9 if positive |
| Annual follow-up | GAD-2 to assess change | PHQ-2 to assess change |
| Clinically indicated | Use judgment; escalate as needed | Use judgment; escalate as needed |
Mental health management in CVD follows a stepped-care approach, escalating intensity based on severity and response to initial interventions.
SSRIs are first-line for CVD patients. They have favorable CV safety but monitor for QTc prolongation (rare), bleeding risk, hyponatremia, and drug interactions.
SSRIs/SNRIs + CBT are preferred for chronic anxiety. Benzodiazepines should be avoided as first-line; short-term use (≤4 weeks) only if necessary, with gradual discontinuation.
| Drug Class | Weight Gain | Hyperglycemia | QTc Risk | Comment |
|---|---|---|---|---|
| SSRIs | Minimal–+ | Minimal | Rare (dose-dependent) | Preferred; monitor QTc if high-dose |
| SNRIs | +–++ | Minimal | Rare | Monitor BP; avoid if uncontrolled HTN |
| Olanzapine/Clozapine | +++ | +++ | + | Highest metabolic risk; intensive monitoring |
| Quetiapine/Risperidone | ++ | ++ | +–++ | Moderate risk; weight/lipid monitoring at baseline & 12 weeks |
| Aripiprazole | 0–+ | 0–+ | Minimal | Lower metabolic risk; preferred if CV concerns |
| Benzodiazepines | + | Minimal | Minimal | Short-term only; taper gradually if >4 weeks |
For any agent with QTc risk (antipsychotics, TCAs, high-dose antidepressants):
Use the QTc Calculator to standardize QT measurement and track changes.
Severe mental illness (SMI) includes schizophrenia, bipolar disorder, and recurrent major depression with functional impairment. CVD risk is 2–3× higher due to lifestyle factors, antipsychotic effects, reduced CV care, and chronic inflammation.
Second-generation antipsychotics vary significantly in metabolic and CV effects:
| Antipsychotic | Weight Gain | Metabolic Risk | QTc Risk |
|---|---|---|---|
| Aripiprazole | Minimal–+ | Minimal | Minimal |
| Lurasidone | + (mild) | 0–+ | + |
| Quetiapine | ++–+++ | ++ | ++ |
| Risperidone | ++ | ++ | + |
| Olanzapine/Clozapine | +++ | +++ | + |
Effective management requires high-intensity collaboration, comprehensive risk assessment, medication optimization (lowest CV risk agents), lifestyle interventions, and regular CV monitoring.
Optimal outcomes require a Psycho-Cardio team including CV specialists, psychiatrists, primary care providers, nurses, and allied health professionals working collaboratively.
Partners and family members are crucial pillars of support yet often experience significant strain. Use the LRAER model:
An integrated support system ensures people with CVD and caregivers have timely access to clinical assessment, education, mental health support, medication management, social care, secondary prevention, and team coordination.
Use these evidence-based tools to support screening, risk stratification, and monitoring:
Calculate corrected QT interval using Fridericia or Bazett formula. Essential for monitoring antipsychotics, TCAs, and antidepressants.
Estimate 10-year atherosclerotic cardiovascular disease risk using pooled cohort equations. Baseline assessment for all CVD patients.
ESC cardiovascular risk score for European populations and older adults. Guides intensity of prevention and management.
Assess stroke risk in atrial fibrillation. Relevant for SMI patients (antipsychotics increase AF risk) or arrhythmia management.
Rapid risk stratification in acute chest pain. Useful for distinguishing cardiac vs. anxiety-related chest pain.